The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Success and failure of additional immunosuppressants in steroid-refractory pneumonitis related to immune checkpoint blockade.
 
Jason Beattie
No Relationships to Disclose
 
Paige Fuentes
No Relationships to Disclose
 
Hira Rizvi
No Relationships to Disclose
 
Jia Luo
No Relationships to Disclose
 
Adam Jacob Schoenfeld
No Relationships to Disclose
 
Michael A. Postow
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; Merck; Newlink Genetics; Novartis
Research Funding - Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst)
 
Margaret K. Callahan
Employment - Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Celgene (I); Kleo Pharmaceuticals (I)
Consulting or Advisory Role - AstraZeneca; Immunocore; Merck; Moderna Therapeutics
Research Funding - Bristol-Myers Squibb (Inst)
Other Relationship - Clinical Care Options; Potomac Center for Medical Education
 
Allison Betof Warner
Honoraria - LG Chem
Research Funding - Leap Therapeutics
 
Mohit Chawla
No Relationships to Disclose
 
Matthew David Hellmann
Stock and Other Ownership Interests - Immunai; Shattuck Labs
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Immunai; Merck; Mirati Therapeutics; Nektar; Shattuck Labs; Syndax
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - A patent has been filed by Memorial Sloan Kettering (PCT/US2015/062208) for the use of tumor mutation burden for prediction of immunotherapy efficacy, and which is licensed to Personal Genome Diagnostics. (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb